Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03554759 · ClinicalTrials.gov registry record
Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure
A clinical trial, sponsored by Sobi.
- Terminated
- Registry status
- 50
- Enrollment target
NCT03554759 is a clinical trial that was terminated before completion, run by Sobi. The registered enrollment target is 50 participants.
The verdict
NCT03554759 was terminated before completion, sponsored by Sobi.
- TERMINATED
- Registry status
- 50 participants
- Enrollment target
Study Summary
Phase 4 observational cohort study to characterize the treatment patterns and effects of avatrombopag use in patients with thrombocytopenia associated with chronic liver disease who are either undergoing, or have already undergone, a procedure.
Interventions
- DRUG Avatrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2019-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03554759
The ClinicalTrials.gov registry entry for NCT03554759 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sobi, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avatrombopag is the first listed.
NCT03554759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03554759 about?
NCT03554759 is a clinical study titled "Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure". Phase 4 observational cohort study to characterize the treatment patterns and effects of avatrombopag use in patients with thrombocytopenia associated with chronic liver disease who are either undergoing, or have already undergone, a procedure.
What is the current status of trial NCT03554759?
This trial is currently terminated. The enrollment target is 50 participants. The study started on 2018-07-02. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT03554759?
The interventions under investigation include: Avatrombopag (DRUG).
Who is sponsoring clinical trial NCT03554759?
This trial is sponsored by Sobi, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.